Zhenjun Yang
University of Georgia
4 Papers
37 Citations
Zhenjun Yang is an academic researcher from University of Georgia. The author has contributed to research in topics: Prodrug & Guanosine. The author has an hindex of 4, co-authored 4 publications. Previous affiliations of Zhenjun Yang include Yale University.
Chat about Author
Papers
Novel Use of a Guanosine Prodrug Approach To Convert 2',3'-Didehydro-2',3'-Dideoxyguanosine into a Viable Antiviral Agent
TL;DR: A novel use of a guanosine prodrug approach to stabilize the nucleoside yielding the prodrug, cyclo-D4G, which possessed anti-HIV activity and had increased stability, lipophilicity, and solubility, as well as decreased toxicity relative to D4G.
37
Mechanism of Anti-Human Immunodeficiency Virus Activity of β-d-6-Cyclopropylamino-2′,3′-Didehydro-2′,3′-Dideoxyguanosine
Adrian S. Ray,Brenda I. Hernandez-Santiago,Judy S. Mathew,Eisuke Murakami,Carey Bozeman,Meng-Yu Xie,Ginger E. Dutschman,Elizabeth A. Gullen,Zhenjun Yang,Selwyn J. Hurwitz,Yung-Chi Cheng,Chung K. Chu,Harold M. McClure,Raymond F. Schinazi,Karen S. Anderson +14 more
TL;DR: Cyclo-d4G had selective anti-HIV activity in primary blood mononuclear cells (PBMCs), effectively inhibiting the LAI strain of HIV-1 by 50% at 1.1 ± 0.1 μM, and has a lower potential to cause mitochondrial toxicity than 2′,3′-dideoxycytidine and 2′-Didehydro- 3′-deoxythymidine in neuronal cells.
6
Insights into the Molecular Mechanism of Inhibition and Drug Resistance for HIV-1 RT with Carbovir Triphosphate†
Adrian S. Ray,Zhenjun Yang,Junxing Shi,Ann Hobbs,Raymond F. Schinazi,Chung K. Chu,Karen S. Anderson +6 more
TL;DR: This work illustrates how an understanding of the molecular mechanism of inhibition and drug resistance led to the discovery of a novel prodrug of D4G, which shows promise as a potent antiviral especially with the drug resistant M184V HIV-1 RT that is so often encountered in a clinical setting.
Effect of 2'-nor-cyclic GMP against guinea pig cytomegalovirus infection.
TL;DR: The drug, administered at this dosage, was reasonably tolerated by the guinea pigs and showed clinical benefit, and by virus yield reduction and plaque reduction assays, 2'-nor-cGMP was demonstrated to be 15- to 20-fold more potent against GPCMV infection than its parental drug DHPG.